Introduction and Objective: CGM can improve glucose levels for insulin-treated type 2 diabetes (T2D). Small trials have found benefits of CGM for T2D not on insulin therapy (NIT), but a fully powered RCT is needed to provide higher-level evidence for this population. To meet this need, we are conducting a multicenter RCT of CGM use […]
Read MoreMonth: June 2026
1163-OR: Paxlovid Use for SARS-CoV-2 Infection and Two-Year Risk of Diabetes: The COVID-19 and Diabetes Assessment (CODA) Study
Introduction and Objective: SARS-CoV-2 infection is associated with increased risk of diabetes mellitus (DM). Paxlovid (nirmatrelvir/ritonavir) is an antiviral approved for individuals at high risk for severe SARS-CoV-2 infection, but its effect on post-SARS-CoV-2 DM risk is unknown. We examined whether outpatient Paxlovid use was associated with incident DM over 2 years in adults aged […]
Read More1153-OR: A Novel Dual-Endpoint Model to Simultaneously Predict Risks of Type 2 Diabetes and Cardiovascular Disease in Prediabetes
Introduction and Objective: This study aimed to develop and validate a novel dual-endpoint model to simultaneously predict 10-year risks of type 2 diabetes (T2D) and cardiovascular disease (CVD) in individuals with prediabetes, enabling more comprehensive risk stratification.Methods: We included 18,848 participants with prediabetes from the Kailuan cohort for model derivation and internal validation, and 46,828 […]
Read MoreHow Inhaled Insulin Changed Everything for This Teen
Share on PinterestJennifer Seigrist (left) and her daughter Taisie Seigrist (right). Photo by Jennifer Seigrist The FDA has approved Afrezza, an inhaled insulin, for children and adolescents. Taisie Seigrist is a 15-year-old who took part in the clinical trial for Afrezza. Seigrist said the needle-free option has changed her life. When Taisie Seigrist was 10 […]
Read More1222-OR: Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Type 1 Diabetes: A Target Trial Emulation Study
Introduction and Objective: Evidence of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in type 1 diabetes (T1D) is limited to short-term trials with surrogate endpoints. Using real-world data, we aimed to assess long-term clinical outcomes of SGLT2i in T1D.Methods: Using electronic health record data from Optum Labs Data Warehouse, we conducted monthly sequential target trial emulation (SGLT2i initiation […]
Read More1156-OR: Engineered Exosome in 3D Printed Skin Substitutes Contributes to Chronic Diabetic Wounds in Mice with Hind-Limb Ischemia by Regulating Rigidity Sensing
Introduction and Objective: Diabetic foot ulcers complicated by lower limb ischemia are common complications in the person with diabetes, leading to non-traumatic amputations. Currently, there are no specific drugs, and treatment is limited to surgical intervention. This study explores the therapeutic effects and mechanisms of multi-cell fusion-based 3D-printed bioengineered skin, incorporating engineered exosomes, for treating […]
Read More1221-OR: Glycemic Variability Predicts Risk of Progression to Stage 3 Type 1 Diabetes Independent of HbA1c
Introduction and Objective: Detecting dysglycemia at early stages of T1D can prevent DKA and improve long-term outcomes. OGTT, currently recommended for monitoring progression, can be challenging in clinical care. HbA1c is not sufficiently sensitive, particularly in young children. We aimed to identify CGM metrics predicting progression to stage 3 T1D.Methods: 171 participants prospectively followed in […]
Read More1187-OR: Maternal and Offspring High-Fat Diet–Interaction Drives Coordinated Chromatin-Level Tissue Remodeling in Adipose Tissue
Introduction and Objective: Maternal obesity is increasingly recognized as a determinant of long-term metabolic risk in offspring, yet the cellular mechanisms by which maternal nutritional status primes adipose tissue for coordinated remodeling across generations remain poorly defined. Traditional research has focused on metabolic dysfunction, failing to explain why certain maternal-offspring dietary combinations produce distinct phenotypic […]
Read More1200-OR: HER2 Inhibition: A Strategy for Restoring Normoglycemia and Beta-Cell Maturity
Introduction and Objective: Given the urgent clinical need to restore long term blood glucose control, this study has established efficacy of BI-1622, a Her2 inhibitor initially developed for therapy of Her2-associated cancer, for diabetes intervention in preclinical models and human islets.Methods: BI-1622 (10 mg/kg) or vehicle was i.p. injected for 4 weeks into db/db, multiple […]
Read More1155-OR: ISM5059, a Novel Peripherally Restricted NLRP3 Inhibitor, Accelerates Healing of Diabetic Foot Ulcers
Introduction and Objective: Diabetic foot ulcers (DFUs) are chronic, slow-healing wounds characterized by unresolved inflammation affecting a significant proportion of patients with diabetes. Dysregulated NLRP3 inflammasome activation in diabetic wounds contributes to chronic inflammation, impeding tissue repair and promoting ulcer chronicity. NLRP3 expression is significantly upregulated in patients with DFUs compared to healthy controls.Methods: THP-1 […]
Read More